Industry
Life Sciences - Biotech
Fewer than 30% of cancer patients treated with chemotherapy or targeted drugs typically receive a survival benefit, yet oncologists cannot quickly identify who is responding. The RNA Disruption Assay provides an early indication of treatment effectiveness, helping physicians adapt therapy sooner, reduce unnecessary toxicity and waste, and improve outcomes.
